BioNTech SE โ NASDAQ:BNTX
Founder-led company
BioNTech SE stock price today
$112.4
-1.54
-1.36%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 4 hours
BioNTech SE stock price monthly change
+34.14%
month
BioNTech SE stock price quarterly change
+34.14%
quarter
BioNTech SE stock price yearly change
+5.94%
year
BioNTech SE key metrics
Market Cap | 27.08B |
Enterprise value | 11.48B |
P/E | 3.78 |
EV/Sales | 0.94 |
EV/EBITDA | 1.36 |
Price/Sales | 1.91 |
Price/Book | N/A |
PEG ratio | N/A |
EPS | 0.46 |
Revenue | 2.72B |
EBITDA | 55.3M |
Income | 113M |
Revenue Q/Q | -85.30% |
Revenue Y/Y | -77.65% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | 2.03% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want toย keep trackย of and getย notified inย theย smart feed every time fresh news arrives.
Sign up for freeBioNTech SE stock price history
BioNTech SE stock forecast
BioNTech SE financial statements
Average Price Target
$121.73
Potential upside: 8.29%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 167.7M | -190.4M | -113.54% |
|---|---|---|---|
| Sep 2023 | 895.3M | 160.6M | 17.94% |
| Dec 2023 | 1.47B | 457.9M | 30.96% |
| Mar 2024 | 187.6M | -315.1M | -167.96% |
2.17%
Yield TTM
| Payout ratio | 7.76% |
|---|
| 2019 | |
|---|---|
| 2020 | |
| 2021 | |
| 2022 | 1.39% |
| 2023 |
| Jun 2023 | 22225600000 | 2.31B | 10.43% |
|---|---|---|---|
| Sep 2023 | 22207200000 | 2.34B | 10.54% |
| Dec 2023 | 23006300000 | 2.76B | 12% |
| Mar 2024 | 22256800000 | 2.28B | 10.28% |
| Jun 2023 | 4.38B | -2.29B | -163.4M |
|---|---|---|---|
| Sep 2023 | 811.2M | -1.23B | -311M |
| Dec 2023 | 850.9M | -2.69B | -12.9M |
| Mar 2024 | -317.3M | -2.30B | -7.8M |
BioNTech SE alternative data
Biontech
| 19 Feb 2023 | 9 |
|---|---|
| 26 Feb 2023 | 9 |
| 5 Mar 2023 | 8 |
| 12 Mar 2023 | 7 |
| 19 Mar 2023 | 8 |
| 26 Mar 2023 | 10 |
| 2 Apr 2023 | 10 |
| 9 Apr 2023 | 8 |
| 16 Apr 2023 | 9 |
| 23 Apr 2023 | 16 |
| 30 Apr 2023 | 18 |
| 7 May 2023 | 18 |
| 14 May 2023 | 17 |
| 21 May 2023 | 15 |
| 28 May 2023 | 93 |
| 4 Jun 2023 | 48 |
| 11 Jun 2023 | 34 |
| 18 Jun 2023 | 50 |
| 25 Jun 2023 | 46 |
| 2 Jul 2023 | 50 |
Covid 19 Vaccines
| 21 May 2023 | 2 | 3 | 5 |
|---|---|---|---|
| 28 May 2023 | 3 | 4 | 4 |
| 4 Jun 2023 | 1 | 2 | 2 |
| 11 Jun 2023 | 1 | 3 | 5 |
| 18 Jun 2023 | 4 | 3 | 3 |
| 25 Jun 2023 | 3 | 11 | 3 |
| 2 Jul 2023 | 4 | 3 | 4 |
| 9 Jul 2023 | 3 | 2 | 2 |
| 16 Jul 2023 | 5 | 2 | 2 |
| 23 Jul 2023 | 2 | 5 | 0 |
| 30 Jul 2023 | 2 | 1 | 2 |
| 6 Aug 2023 | 5 | 4 | 2 |
| 13 Aug 2023 | 4 | 3 | 2 |
| 20 Aug 2023 | 2 | 2 | 0 |
| 27 Aug 2023 | 46 | 4 | 2 |
| 3 Sep 2023 | 27 | 12 | 19 |
| 10 Sep 2023 | 18 | 13 | 6 |
| 17 Sep 2023 | 28 | 5 | 21 |
| 24 Sep 2023 | 53 | 7 | 14 |
| 1 Oct 2023 | 59 | 8 | 26 |
mRNA
| 11 Jun 2023 | 21 |
|---|---|
| 18 Jun 2023 | 25 |
| 25 Jun 2023 | 16 |
| 2 Jul 2023 | 18 |
| 9 Jul 2023 | 17 |
| 16 Jul 2023 | 19 |
| 23 Jul 2023 | 19 |
| 30 Jul 2023 | 16 |
| 6 Aug 2023 | 19 |
| 13 Aug 2023 | 17 |
| 20 Aug 2023 | 17 |
| 27 Aug 2023 | 15 |
| 3 Sep 2023 | 19 |
| 10 Sep 2023 | 14 |
| 17 Sep 2023 | 39 |
| 24 Sep 2023 | 63 |
| 1 Oct 2023 | 43 |
| 8 Oct 2023 | 80 |
| 15 Oct 2023 | 82 |
| 22 Oct 2023 | 99 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
What is job openings count?
| Aug 2023 | 408 |
|---|---|
| Sep 2023 | 424 |
| Oct 2023 | 389 |
| Nov 2023 | 368 |
| Dec 2023 | 387 |
| Jan 2025 | 145 |
| Feb 2025 | 134 |
| May 2025 | 124 |
| Jul 2025 | 123 |
| Aug 2025 | 100 |
| Aug 2023 | 5,100 |
|---|---|
| Sep 2023 | 5,500 |
| Oct 2023 | 5,500 |
| Nov 2023 | 5,500 |
| Dec 2023 | 5,500 |
| Jan 2024 | 5,500 |
| Feb 2024 | 5,700 |
| Mar 2024 | 6,133 |
| Apr 2024 | 6,133 |
| May 2024 | 6,133 |
| Jun 2024 | 6,133 |
| Jul 2024 | 6,133 |
BioNTech SE other data
10.88%
-4.40%
of BNTX is owned by hedgeย funds
185
-123
27.17M
-12.49M
shares is hold by hedgeย funds
| Patent |
|---|
Grant Filling date: 11 Jun 2021 Issue date: 13 Sep 2022 |
Application Filling date: 30 Dec 2021 Issue date: 1 Sep 2022 |
Application Filling date: 7 Mar 2022 Issue date: 18 Aug 2022 |
Application Filling date: 20 May 2020 Issue date: 18 Aug 2022 |
Application Lipid Particle Formulations for Delivery of RNA and Water-Soluble Therapeutically Effective Compounds to a Target Cell Filling date: 25 Apr 2022 Issue date: 11 Aug 2022 |
Application Filling date: 30 Dec 2021 Issue date: 11 Aug 2022 |
Application Filling date: 10 Feb 2022 Issue date: 4 Aug 2022 |
Grant Filling date: 18 Oct 2018 Issue date: 26 Jul 2022 |
Application Filling date: 1 Feb 2022 Issue date: 21 Jul 2022 |
Application Filling date: 2 Apr 2020 Issue date: 12 May 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 6 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 20 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 6 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 7 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Sean Marett (1966) Chief Bus. Officer, Chief Commercial Officer & Member of Management Board | $761,750 |
Dr. Sierk Poetting Ph.D. (1974) MD, Chief Operating Officer & Member of Management Board | $688,290 |
Prof. Ugur Sahin M.D. (1966) Co-Founder, Chief Executive Officer & Member of Management Board | $682,640 |
Dr. Ozlem Tureci M.D. (1968) Chief Medical Officer & Member of Management Board | $675,860 |
Mr. Ryan Richardson (1980) Chief Strategy Officer, MD & Member of Management Board | $606,920 |
Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment
Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success
Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)
Arbutus: Positive Imdusiran Data Leads To Phase 2B Development
Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity
Week In Review: MediLink And BioNTech Form $1.8B ADC Partnership
Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity
-
What's the price of BioNTech SE stock today?
One share of BioNTech SE stock can currently be purchased for approximately $112.4.
-
When is BioNTech SE's next earnings date?
Unfortunately, BioNTech SE's (BNTX) next earnings date is currently unknown.
-
Does BioNTech SE pay dividends?
Yes, BioNTech SE pays dividends and its trailing 12-month yield is 2.17% with 8% payout ratio. The last BioNTech SE stock dividend of undefined was paid on 25 Sep 2025.
-
How much money does BioNTech SE make?
BioNTech SE has a market capitalization of 27.08B and it's past yearsโ income statements indicate that its last revenue has decreased compared to the previous period by 77.94% to 3.82B US dollars.
-
What is BioNTech SE's stock symbol?
BioNTech SE is traded on the NASDAQ under the ticker symbol "BNTX".
-
What is BioNTech SE's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of BioNTech SE?
Shares of BioNTech SE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are BioNTech SE's key executives?
BioNTech SE's management team includes the following people:
- Mr. Sean Marett Chief Bus. Officer, Chief Commercial Officer & Member of Management Board(age: 59, pay: $761,750)
- Dr. Sierk Poetting Ph.D. MD, Chief Operating Officer & Member of Management Board(age: 51, pay: $688,290)
- Prof. Ugur Sahin M.D. Co-Founder, Chief Executive Officer & Member of Management Board(age: 59, pay: $682,640)
- Dr. Ozlem Tureci M.D. Chief Medical Officer & Member of Management Board(age: 57, pay: $675,860)
- Mr. Ryan Richardson Chief Strategy Officer, MD & Member of Management Board(age: 45, pay: $606,920)
-
Is BioNTech SE founder-led company?
Yes, BioNTech SE is a company led by its founder Prof. Ugur Sahin M.D..
-
How many employees does BioNTech SE have?
As Jul 2024, BioNTech SE employs 6,133 workers.
-
When BioNTech SE went public?
BioNTech SE is publicly traded company for more then 5 years since IPO on 10 Oct 2019.
-
What is BioNTech SE's official website?
The official website for BioNTech SE is biontech.de.
-
How can i contact BioNTech SE?
BioNTech SE can be reached via phone at +49 6131 90840.
-
What is BioNTech SE stock forecast & price target?
Based on 9 Wall Street analysts` predicted price targets for BioNTech SE in the last 12 months, the avarage price target is $121.73. The average price target represents a 8.29% change from the last price of $112.4.
BioNTech SE company profile:
BioNTech SE
biontech.deExchange:
NASDAQ
Full time employees:
6,133
Industry:
Biotechnology
Sector:
Healthcare
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
An der Goldgrube 12
Mainz, 55131
Mainz, 55131
CIK: 0001776985
ISIN: US09075V1026
CUSIP: 09075V102
